Emerging treatments
Semaglutide
An alternative glucagon-like peptide-1 (GLP-1) receptor agonist that is approved for use in type 2 diabetes in adults, but not children. However, semaglutide is approved for the management of obesity in children ages ≥12 years with a BMI in the 95th percentile or higher for their age and sex. The brands of semaglutide approved for use in type 2 diabetes and obesity are different, and the doses used are also different.
Endoscopic bariatric procedures
Stand-alone, primary endoscopic bariatric procedures (e.g., intragastric balloons) for the management of obesity and certain obesity-associated comorbidities like type 2 diabetes, have evolved in recent years, bridging the gap between intensive lifestyle modifications and invasive bariatric surgical procedures.[89] In general, endoscopic bariatric procedures appear to be slightly less efficacious than bariatric surgery, although they are potentially slightly safer, less-invasive, and more reversible.[89]
Use of this content is subject to our disclaimer